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Systematic use of the live attenuared mumps vaccines for the last four decades 
significantly reduced the incidence of disease and even resulted in its eradication in 
some parts of the world (1, 2). However, reactogenicity due to a poor attenuation, the 
possibility of vaccine strain shedding and horizontal transmission represent some 
problems related with some mumps vaccine strains (3, 4, 5, 6, 7). Although virus 
shedding following immunization with certain live attenuated mumps vaccine strain 
has been well documented, it is generally accepted that horizontal transmission of 
vaccine strains is a rare event, and to the best of our knowledge until now there have 
been only two reports in whom symptomatic disease developed as a consequence (6, 
7). Sawada et al. described in 1993 a horizontal transmission of the Urabe AM9 
vaccine strain from a symptomatic vaccinee to her younger sister (6), while recently a 
horizontal transmission of the Leningrad-3 mumps vaccine strain from healthy 
vaccinees to six previously vaccinated contacts resulting in symptomatic infection, has 
been described (7). In both studies, parotitis developed as a unique consequence of 
horizontal transmission of mumps vaccine strains. Neither neurological, nor other 
extrasalivary abnormalities were seen among those patients, and none of them had to 
be hospitalized. All patients were in childhood age (6, 7).  
In Croatia the measles, mumps and rubella (MMR) vaccine containing 
Leningrad-Zagreb (L-Z) mumps vaccine strain has been a part of routine 
immunization programme for thirty-one years (9). L-Z, originating from the Russian 
Leningrad-3 vaccine strain, has been successfully used in other parts of the former 
Yugoslavia, as well as in some of the developing countries (1, 10). L-Z is a very 
immunogenic and efficacious strain, but even serious adverse reactions (e.g. aseptic 
meningitis), especially after primovaccination have been reported (9, 10, 11, 12). 
Although reactogenicity of L-Z strain, has been confirmed, and viremia and viral 
shedding among vaccinees is a probable event, not a single case of horizontal 
transmission of L-Z mumps vaccine strain has been reported to date in peer-review 
journals. 
After two cases of parotitis in adults temporarily associated with recent MMR 
vaccination of their children were recorded in Croatia during 2004 and 2005 (data not 
published), we started a prospective observational study of all parotitis cases at the 
University Hospital for Infectious Diseases (UHID), in Zagreb, Croatia in order to 
confirm the existence of horizontal transmission of the L-Z vaccine strain. The study 
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started on November 1, 2006 and finished on October 31, 2007. In the observed period 
16 patients with clinically evident parotitis were seen at the UHID, of whom four were 
suspected of becoming infected by a horizontal transmission of mumps vaccine strain. 
During the study period 16 600 doses of MMR vaccine containing L-Z vaccinal strain 
have been administered in Zagreb and its vicinity.  
Patients eligible for this study were selected on the basis of the following 
criteria: (i) no history of recent vaccination against mumps; (ii) contact with a recently 
vaccinated person, i. e. within 45 days prior to development of first symptoms of 
disease and (iii) negative results of parainfluenza virus types 1, 2 and 3 and Epstein-
Barr virus (EBV) serology (13). In one patient all samples tested negative for mumps 
virus RNA, while in three patients (P1 – P3) with suspected horizontal transmission, 
an infection with L-Z strain was confirmed (Table 1). A possible source of infection in 
all three cases were their own children recently vaccinated with L-Z containing 
vaccine. Vaccination histories of all patients were collected through interviews. P1 and 
P2 were vaccinated in early childhood with one dose of MMR containing L-Z vaccine 
strain, while P3 was previously unvaccinated (Table 1).  
All three patients included in the study were adults. Both P2 and P3 had 
parotitis while P1 had parotitis, orchitis and AM. P2 and P3 were treated as 
outpatientswhile P1 was hospitalized for five days. No neurological sequelae were 
seen nor subjective complaints registered at the follow-up visit of P1 two months after 
the discharge. 
In P1, urine and CSF samples for molecular analysis, and serum for serology 
were taken on the 2nd day of hospitalization. Throat swabs, urine samples and serum 
taken at the first visit were obtained from P2 and P3 (Table 1).  
 
Samples for mumps virus detection (throat swabs, urine and CSF) were stored 
at -80°C and then transferred to the Institute of Microbiology and Immunology, 
Faculty of Medicine, University of Ljubljana, Slovenia. A sample of freeze-dried L-Z 
mumps vaccine, batch No. 119R (Institute of Immunology, Zagreb, Croatia), 
reconstituted in 500µl of sterile water prior to RNA extraction, was used as a positive 
control. Viral RNA was extracted from clinical and vaccine samples using QiaAmp 
Viral RNA mini kit (Qiagen, Hilden, Germany), according to the manufacturer's 
instructions. Briefly, 560 µl of AVL buffer containing carrier RNA was added to 140 
µl of throat swab suspension, urine, CSF or vaccine sample and incubated 10 minutes 
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at room temperature. After the addition of 96% ethanol, each sample was transferred 
into a QIAamp Mini spin column, centrifuged for 1 min at 8,000 rpm, and then 
washed with AW1 and AW2 buffers. Bound RNA was double eluted with 40 µl of 
AVE buffer. Prior to RNA extraction urine samples were centrifuged for 10 min at 
1500 x g and only the supernatant was used.  
A slightly modified nested SH/LZ RT-PCR assay, specific for mumps virus SH 
gene, was used to detect mumps RNA using the outer primer set SH1/SH2 for the first 
PCR amplification and the inner primer set LZ1/LZ2 for the second step, as described 
previously (14). Briefly, the first PCR was carried out using OneStep RT-PCR Kit 
(Qiagen) in a 25 µl reaction volume, that included 5 µl of extracted RNA, 5 µl of 5x  
QIAGEN OneStep RT-PCR buffer with 12.5 MgCl2, 400 µM dNTP, 1 µl of QIAGEN 
OneStep RT-PCR Enzyme Mix, 4 U of RNase inhibitor and 600 nM of each SH 
primer. The cycling conditions used were 50°C for 30 min, 95°C for 15 min, followed 
by 40 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 2 min. This was followed by 
a final extension step at 72°C for 10 min, and the amplification reaction mixtures were 
cooled to 4°C. The second PCR was performed using HotStar Taq Plus DNA 
Polymerase kit (Qiagen) in a 50 µl reaction volume that included 2 µl of the first-step 
PCR product, 5 µl 10x CoralLoad PCR buffer with 15 mM MgCl2, 200 µM dNTP, 2.5 
U of HotStar Taq Plus DNA Polymerase and 200 nM of each LZ primer. The cycling 
conditions used were 95°C for 5 min, followed by 30 cycles of 94°C for 30 s, 55°C for 
30 s and 72°C for 2 min, followed by a final extension step at 72°C for 10 min, and 
the amplification reaction mixtures were stored at 4°C. The amplified PCR products 
were purified by QIAquick PCR Purification Kit (Qiagen) and sequenced directly 
using BigDye Terminator v1.1 Cycle Sequencing Kit (PE Applied Biosystems, Foster 
City, CA) with LZ1/LZ2 primers. Sequencing products were purified of 
unincorporated dye labeled dideoxynucleotides by processing through DyeExTM 2.0 
Spin Kit spin columns (Qiagen). Sequence analysis was performed using ABI 
PRISMTM 310 Genetic Analyzer (PE Applied Biosystems, Foster City, CA) and the 
complementary sequences were aligned and edited with BioEdit Sequence Alignment 
Editor (North Carolina State University, Raleigh, NC). A comparison of the obtained 
nucleotide sequences with those available in GenBank was performed using the 
BLAST server (http://www.ncbi.nlm.nih.gov/BLAST). Results from the BLAST 
comparisons were confirmed additionally by ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw/) multiple alignments using the sequence of 
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interest and reference sequences of L-Z vaccine (GenBank accession number 
AY685920) and master seed strain (GenBank accession number AY685921).  
The patients` sera were processed at the serological laboratory of the UHID 
and at Virology Department of the Croatian National Institute of Public Health. Recent 
infection with parainfluenza viruses and Epstein-Barr virus (EBV) was excluded using 
commercial Virotech ParaScreen ELISA kit (Genzyme Virotech GmbH, Russelsheim, 
Germany) and LIAISON EBV kit (DiaSorin, Saluggia, Italy), respectively. Infection 
with parainfluenza virus types 1 – 3 was excluded if specific IgM and IgA antibodies 
were not detected. Recent EBV infection was excluded if IgM to viral capsid antigen 
(EBV VCA) and/or IgG to early antigen (EBV EA) were not detected. 
Serological detection of anti-mumps virus IgM and IgG antibodies was done 
by Virotech Mumps ELISA kit (Genzyme Virotech GmbH, Russelsheim, Germany). 
Quantitative IgM and IgG results were classified as positive, equivocal or negative 
according to the manufacturer`s recommendations: > 11 Virotech Units (VE) positive; 
9 – 11 VE equivocal and < 9 VE negative.  
Neutralizing anti-mumps antibodies were determined by the procedure 
described by Örvell et al., slightly modified to the microtechnique (15). Briefly, serial 
twofold dilutions of the patients’ sera in a volume of 0.05 ml were mixed with an 
equal volume of L-Z mumps vaccine strain (100 TCID50/0.1ml) in flat-bottomed cell 
culture microtitre plate. Two wells were inoculated per one serum dilution, with 
dilution range of 1:4 – 1:128. Serum/virus mixtures were incubated at 37°C, 5% CO2 
for 1 hour. During this incubation period a suspension of approximately 1.5 x 10-5 cells 
per ml of Vero cells was prepared in MEM (Invitrogen, Paisley, UK) with hepes, 
supplemented with 2% foetal bovine serum, and distributed 0.1 ml of cell suspension 
into all wells. Plates were incubated at 37°C, 5% CO2, and daily inspected for 
cytopathic effect with final readings after 5 days of incubation. For each serum, the 
neutralizing antibody titer was determined as the highest dilution in which cytopathic 
effect was not observed. The cut-off for seropositivity was a neutralizing antibody titer 
≥ 1:4.  
Mumps virus RNA was detected in vaccine sample and in four (66.7%) out of 
six clinical samples tested (Table 1). In P1 viral RNA was detected in CSF sample 
only. In P2, both the throat swab and urine sample were positive for viral RNA, while 
in P3 mumps virus RNA was successfully amplified from throat swab sample.  
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Direct sequencing of the approximately 330-bp long LZ PCR product of four 
mumps virus RNA positive samples revealed that the all three patients were infected 
with the L-Z mumps vaccine strain. The SH sequences obtained from al three patients 
matched completely (100%) the SH reference sequences of the L-Z vaccine and 
master seed strains, available in GenBank. 
Specific IgG and IgM antibody levels as well as neutralizing antibody titers of 
all patients are presented in Table 1. All three patients were IgM-negative but had 
detectable levels of specific anti-mumps IgG antibodies. Neutralizing antibodies were 
detected only in serum sample of the P1, although the titer was low (1:8).  
 
Horizontal transmission of mumps vaccine strains is a very rare event, and to 
the best of our knowledge until now only transmission among persons of childhood 
age has been described. All subjects in whom symptomatic disease developed as a 
consequence of horizontal transmission of vaccine strain had parotitis of benign course 
(7, 8). No single case of symptomatic disease following horizontal transmission of 
mumps vaccine in an adult person has been reported to date, as well as no case of 
extrasalivary localization of infection. In contrast to previously reported cases, all 
three patients described in the present study were adult persons, one of whom 
developed two extrasalivary complications requiring hospitalization.  
The possible source of infection in our patients was their own children who 
were recently primovaccinated with L-Z containing MMR vaccine. First symptoms of 
disease in patients appeared within 33 – 44 days after the vaccination of their children. 
Taking into account the duration of incubation period in natural mumps infection, as 
well as the timing of clinical presentation of previously described L-Z vaccinal 
complications, our data, although scarce, may suggest that viral shedding might have 
happened two to four weeks after the vaccination, which is consistent with the 
published data (8, 12, 16).  
In all our patients, the infection with L-Z was confirmed using RT-PCR 
targeting SH gene. Viral RNA was detected in throat swabs of P2 and P3 and in urine 
and CSF samples of P2 and P1, respectively. Interestingly, viral RNA was detected in 
only one out of three urine samples tested, although viruria in mumps infection is a 
frequent and long lasting event (16). The presence of variable amounts of PCR 
inhibitors in the eluate could be the reason why the detection of mumps virus RNA in 
urine was less successful than in other clinical samples (17).  
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All three patients in our study had detectable anti-mumps IgG antibodies. The 
most plausible explanation for the presence of specific anti-mumps antibodies in P1 
and P2 might be the immunization with L-Z in early childhood, although all our 
patients were born in the period when epidemic parotitis was common in Croatian 
population, and previous asymptomatic infection with a wild strain can be another 
possibility (9). Despite the presence of anti-mumps IgG antibodies, P1 had a very low 
titer (1:8), while P2 and P3 had undetectable neutralizing antibody levels. Our results 
thus support previously known facts that total IgG is not an appropriate correlate of 
protection to reinfection with mumps virus, and that ELISA is capable to detect a wide 
spectrum of anti-mumps antibodies, of which only a small proportion are able to 
neutralize the virus (7, 18). Low, or undetectable level of neutralizing anti-mumps 
antibodies provided the explanation why contact with a vaccine strain resulted in 
symptomatic infection. 
In conclusion, the present report describes the first virologically confirmed 
cases of symptomatic mumps following horizontal transmission of mumps vaccine 
strain in adults. Our data suggest that the L-Z mumps vaccine strain can be transmitted 
horizontally, causing parotitis, as well as extrasalivary manifestations of the disease 
including meningitis, even among previously vaccinated subjects. Thus, a close 
monitoring of vaccinated children family members, especially mumps virus naive or 
those who had been vaccinated long time ago is highly advisable.   
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Table 1 
Epidemiologic, clinical, RT-PCR and serologic data of patients with confirmed L-Z mumps infection 
 
Patient  Age 
(years) 
Sex Previously 
vaccinated 
Clinical 
presentation 
Source 
of 
infection 
Date of 
child`s 
vaccination 
Date of first 
presentation 
Date of 
sampling 
RT-
PCR 
throat 
swab 
RT-
PCR 
urine 
RT-
PCR 
CSF 
ELISA 
IgM 
(VE) 
ELISA 
IgG 
(VE) 
NT 
(titer) 
P 1 29 M yes Pa, O, AM son May, 10 June, 12 June, 17 NC neg pos neg 43 1:8 
P 2 30 M yes Pa son July, 12 August, 25 August, 26 pos pos NC neg 48 <1:4 
P 3 37 F no Pa daughter August, 28 October, 11 October, 12 pos neg NC neg 51 <1:4 
 
 
Pa, parotitis; O, orchitis; AM, aseptic meningitis; NC, not collected; M, male; F, female; neg, negative; pos, positive. 
